GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.

@article{Armstrong2012GPIIbIIIaIF,
  title={GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.},
  author={Paul C J Armstrong and Karlheinz Dr. Peter},
  journal={Thrombosis and haemostasis},
  year={2012},
  volume={107 5},
  pages={
          808-14
        }
}
From the discovery of the platelet glycoprotein (GP) IIb/IIIa and identification of its central role in haemostasis, the integrin GPIIb/IIIa (αIIbβ3, CD41/CD61) was destined to be an anti-thrombotic target. The subsequent successful development of intravenous ligand-mimetic inhibitors occurred during a time of limited understanding of integrin physiology. Although efficient inhibitors of ligand binding, they also mimic ligand function. In the case of GPIIb/IIIa inhibitors, despite strongly… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 89 REFERENCES

Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization: A Meta-Analysis of Randomized Trials Performed in the Era of Stents and Thienopyridines

  • DE Winchester
  • J Am Coll Cardiol
  • 2011

Molecular mechanism of inside-out integrin regulation

  • F Ye
  • J Thromb Haemost ;
  • 2011

Similar Papers

Loading similar papers…